Short answer
Anteris Technologies Global Corp. (AVR) filed its Q2 2026 10-Q quarterly report on Aug 11, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $1M (up 63.3% year over year) with net income of −$29M.
Q2 2026 key financials · XBRL
- Revenue
- $1M
- +63.3% YoY · +104.3% QoQ
- Net income
- −$29M
- −39.6% YoY · −26.4% QoQ
- Operating margin
- -3072.1%
- EPS (diluted)
- −$0.30
- +47.4% YoY · −7.1% QoQ
Source: XBRL data from the Anteris Technologies Global Corp. (AVR) Q2 2026 10-Q on SEC EDGAR. USD.
Anteris Technologies Global Corp. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Q2 revenue $1.0M vs $0.6M YoY, up 63%, driven by tissue-product sales to 4C
- Gross margin generally consistent YoY; operating loss $31.0M vs $20.9M
- Single segment: DurAVR THV System development; 4C tissue sales increased 63% to $1.0M
- Cash $260.9M at June 30; operating cash outflow $49.5M vs $41.0M
- Financing provided $298.6M, including $308.3M net stock proceeds; losses expected near term and cash sufficient for at least 12 months
Risk Factors
- Newly added risk: PARADIGM Trial failure, following FDA IDE approval
- Regulatory risk: FDA approval may be revoked or require costly post-market testing
- Operational risk: Trial delays could prevent DurAVR THV System revenue and profitability
- Compliance risk: FDA enforcement or inquiries could discourage physician adoption
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Anteris Technologies Global Corp. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.